London
· Delayed Price · Currency is GBP · Price in USD Atara Biotherapeutics Statistics
Total Valuation
Atara Biotherapeutics has a market cap or net worth of GBP 32.22 million. The enterprise value is 18.18 million.
| Market Cap | 32.22M |
| Enterprise Value | 18.18M |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +40.71% |
| Shares Change (QoQ) | +21.54% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 4.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.18 |
| EV / Sales | 0.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.26 |
Financial Position
The company has a current ratio of 0.59
| Current Ratio | 0.59 |
| Quick Ratio | 0.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -25.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -45.03% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 471,305 |
| Profits Per Employee | -624,847 |
| Employee Count | 225 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 17.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.02% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -63.02% |
| 50-Day Moving Average | 12.21 |
| 200-Day Moving Average | 11.51 |
| Relative Strength Index (RSI) | 30.99 |
| Average Volume (20 Days) | 11,119 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.77 |
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of GBP 74.94 million and -99.35 million in losses. Loss per share was -16.86.
| Revenue | 74.94M |
| Gross Profit | -59.63M |
| Operating Income | -89.09M |
| Pretax Income | -99.34M |
| Net Income | -99.35M |
| EBITDA | -85.24M |
| EBIT | -89.09M |
| Loss Per Share | -16.86 |
Balance Sheet
The company has 50.13 million in cash and 37.23 million in debt, giving a net cash position of 12.90 million.
| Cash & Cash Equivalents | 50.13M |
| Total Debt | 37.23M |
| Net Cash | 12.90M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -67.55M |
| Book Value Per Share | -11.77 |
| Working Capital | -47.84M |
Cash Flow
In the last 12 months, operating cash flow was -70.62 million and capital expenditures -149,220, giving a free cash flow of -70.77 million.
| Operating Cash Flow | -70.62M |
| Capital Expenditures | -149,220 |
| Free Cash Flow | -70.77M |
| FCF Per Share | n/a |
Margins
Gross margin is -79.58%, with operating and profit margins of -118.88% and -132.58%.
| Gross Margin | -79.58% |
| Operating Margin | -118.88% |
| Pretax Margin | -132.56% |
| Profit Margin | -132.58% |
| EBITDA Margin | -113.75% |
| EBIT Margin | -118.88% |
| FCF Margin | n/a |
Dividends & Yields
Atara Biotherapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.71% |
| Shareholder Yield | -40.71% |
| Earnings Yield | -308.33% |
| FCF Yield | -219.63% |
Stock Splits
The last stock split was on June 20, 2024. It was a reverse split with a ratio of 0.04.
| Last Split Date | Jun 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Atara Biotherapeutics has an Altman Z-Score of -22.45. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.45 |
| Piotroski F-Score | n/a |